Healthcare Wrap: Echo IQ and INOVIQ surge as funding and data drive the week

Echo IQ (ASX:EIQ) led the week with a 29.80% rise after securing a binding agreement for a strategic investment from Pro Medicus and a US reseller deal. INOVIQ (ASX:IIQ) was close behind, up 29.76%, after reporting early lab results that killed more than 90% of ovarian cancer cells in some tests. On the downside, Imagion Biosystems (ASX:IBX) dropped 20.00% despite raising A$3.75 million to start a US breast cancer imaging trial. Investors often like fresh cash, but they can still sell when new shares are issued at a low price because their stake is diluted, which means each existing share represents a smaller slice of the company.

AI and imaging names drew the strongest buying

Echo IQ's deal mattered because it did two things at once. It brought in funding and it opened a sales channel through Pro Medicus' hospital network in the US. For a small healthcare software company, that can be more important than a simple cash injection. Investors are now waiting for US regulatory clearance for EchoSolv HF, which is the trigger for the second A$10 million tranche. Pro Medicus (ASX:PME) also gained, rising 9.31%, as the market backed its plan to add more AI tools to its cardiology platform. Elsewhere in imaging, 4DMedical (ASX:4DX) slipped 8.37% even after winning Australian approval for CT:VQ™, a lung imaging software product. The approval allows sales in Australia, but investors still want to see Medicare funding progress because doctors and hospitals are more likely to use a product if reimbursement is in place. CONNEQT Health (ASX:CQT) fell 4.35% after lodging an FDA pre-submission for its cloud cardiovascular software. That filing is an early step, not a final approval, so revenue remains some way off.

Drug developers advanced trials, but cash needs stayed front of mind

AFT Pharmaceuticals (ASX:AFP) gave the sector one of its strongest operating updates. Revenue rose 22% to NZ$254.7 million, operating profit reached NZ$24.4 million, and the FDA cleared a Phase III trial for its injectable iron project. Phase III is a late-stage human trial, usually run to prove a treatment works well enough and safely enough for a final approval application. Investors cared because AFT is already profitable and selling into 87 countries, which makes the iron program feel less speculative than a typical biotech story. Recce Pharmaceuticals (ASX:RCE) had a busy week but still fell 16.67%. It broadened its Phase 3 diabetic foot infection trial and raised A$4 million, with a share purchase plan for up to another A$4 million. The clinical news was constructive. The share price reaction suggests investors were more worried about dilution and the time needed to finish the studies than excited by the protocol change. Imagion faced a similar issue. Its capital raise funds trial start-up and manufacturing, but the immediate effect was more stock on issue. Several smaller names also tapped investors for cash. Control Bionics (ASX:CBL) fell 9.89% after announcing a A$10 million raising for expansion and research. EBR Systems (ASX:EBR) eased 2.63% after closing the retail part of a larger A$43.6 million offer. In both cases, the money helps fund growth, but the discount on new shares can weigh on the price in the short term.

Takeovers and contracts offered clearer near-term outcomes

SDI Limited (ASX:SDI) edged up 0.36% as its A$1.40 a share acquisition moved through the final steps. Shareholders had already backed the scheme with 98.37% support, and the Supreme Court of New South Wales then approved it. With the stock set for ASX suspension on 25 June and implementation targeted for 6 July, the share price had little room to move far from the cash offer. Healius (ASX:HLS) fell 10.98% even after landing a pathology agreement with Ramsay Health Care worth about A$45 million a year. The contract gives useful revenue across 13 hospitals, but investors may want proof that this can offset broader pressures in healthcare services. Pacific Edge (ASX:PEB) also stayed under pressure, down 2.04%, after reporting a steep revenue decline and a FY26 loss. A proposed US Medicare policy could improve test coverage, but it is still only a draft.

Gap moves split between follow-through buying and early enthusiasm fading

A few small-cap names reopened with large price gaps, then took different paths. INOVIQ held onto strong buying after its jump and kept climbing through the session, which usually means investors believed the news had changed the company's prospects. Skin Elements (ASX:SKN) rose 20.00% for the week after a discounted placement and leadership change, but the stock went nowhere after reopening. That suggests early buyers were not prepared to keep pushing the price higher. TruScreen (ASX:TRU) lost 12.50% for the week, and the stock fell again after reopening, even though its rights issue was oversubscribed. Early gains evaporated as traders focused on the large number of new shares issued. Osteopore (ASX:OSX), up 12.50%, also stalled after its reopening despite another note drawdown. Outside those names, Memphasys (ASX:MEM) gained 16.67% after reporting UK trial activity and early orders for its fertility product. Mesoblast (ASX:MSB) dropped 11.50% even though it refinanced debt more cheaply, while ECS Botanics (ASX:ECS) fell 11.11% after launching a new cannabis cultivar. In both cases, the announcements were positive on paper, but they did not trigger enough fresh buying to overcome existing caution.